277 related articles for article (PubMed ID: 30589922)
1. Month 12 Outcomes After Treatment Change at Month 6 Among Poor Responders to Aflibercept or Bevacizumab in Eyes With Macular Edema Secondary to Central or Hemiretinal Vein Occlusion: A Secondary Analysis of the SCORE2 Study.
Ip MS; Oden NL; Scott IU; VanVeldhuisen PC; Blodi BA; Ghuman T; Baker CW;
JAMA Ophthalmol; 2019 Mar; 137(3):281-287. PubMed ID: 30589922
[TBL] [Abstract][Full Text] [Related]
2. Month 24 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: SCORE2 Report 10: A Secondary Analysis of the SCORE2 Randomized Clinical Trial.
Scott IU; Oden NL; VanVeldhuisen PC; Ip MS; Blodi BA; Chan CK;
JAMA Ophthalmol; 2019 Dec; 137(12):1389-1398. PubMed ID: 31600368
[TBL] [Abstract][Full Text] [Related]
3. Baseline Characteristics and Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema in Participants With Hemiretinal Vein Occlusion Compared With Participants With Central Retinal Vein Occlusion: Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Report 18.
Scott IU; Oden NL; VanVeldhuisen PC; Ip MS; Blodi BA;
JAMA Ophthalmol; 2022 May; 140(5):458-464. PubMed ID: 35323843
[TBL] [Abstract][Full Text] [Related]
4. Baseline Factors Associated With 6-Month Visual Acuity and Retinal Thickness Outcomes in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Study Report 4.
Scott IU; VanVeldhuisen PC; Ip MS; Blodi BA; Oden NL; King J; Antoszyk AN; Peters MA; Tolentino M;
JAMA Ophthalmol; 2017 Jun; 135(6):639-649. PubMed ID: 28492860
[TBL] [Abstract][Full Text] [Related]
5. Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial.
Scott IU; VanVeldhuisen PC; Ip MS; Blodi BA; Oden NL; Awh CC; Kunimoto DY; Marcus DM; Wroblewski JJ; King J;
JAMA; 2017 May; 317(20):2072-2087. PubMed ID: 28492910
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Monthly vs Treat-and-Extend Regimens for Individuals With Macular Edema Who Respond Well to Anti-Vascular Endothelial Growth Factor Medications: Secondary Outcomes From the SCORE2 Randomized Clinical Trial.
Scott IU; VanVeldhuisen PC; Ip MS; Blodi BA; Oden NL; Altaweel M; Berinstein DM;
JAMA Ophthalmol; 2018 Apr; 136(4):337-345. PubMed ID: 29476687
[TBL] [Abstract][Full Text] [Related]
7. SCORE2 Report 24: Nonlinear Relationship of Retinal Thickness and Visual Acuity in Central Retinal and Hemiretinal Vein Occlusion.
Scott IU; Oden NL; VanVeldhuisen PC; Ip MS; Blodi BA;
Ophthalmology; 2023 Oct; 130(10):1066-1072. PubMed ID: 37220815
[TBL] [Abstract][Full Text] [Related]
8. SCORE2 Report 2: Study Design and Baseline Characteristics.
Scott IU; VanVeldhuisen PC; Ip MS; Blodi BA; Oden NL; Figueroa M; Dugel PU;
Ophthalmology; 2017 Feb; 124(2):245-256. PubMed ID: 27863843
[TBL] [Abstract][Full Text] [Related]
9. Cost-Utility Comparison of Bevacizumab and Aflibercept in the Treatment of Central or Hemiretinal Vein Occlusion in the SCORE2 Trial.
Kymes SM; Oden NL; VanVeldhuisen PC; Scott IU; Ip MS; Blodi BA; King J;
JAMA Ophthalmol; 2023 Jun; 141(6):554-561. PubMed ID: 37166820
[TBL] [Abstract][Full Text] [Related]
10. SCORE2 Report 13: Intraretinal Hemorrhage Changes in Eyes With Central or Hemiretinal Vein Occlusion Managed With Aflibercept, Bevacizumab or Observation. Secondary Analysis of the SCORE and SCORE2 Clinical Trials.
Hendrick A; VanVeldhuisen PC; Scott IU; King J; Blodi BA; Ip MS; Khurana RN; Oden NL;
Am J Ophthalmol; 2021 Feb; 222():185-193. PubMed ID: 32828880
[TBL] [Abstract][Full Text] [Related]
11. Intraocular Pressure-Related Events After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical Trial.
Aref AA; Scott IU; VanVeldhuisen PC; King J; Ip MS; Blodi BA; Oden NL;
JAMA Ophthalmol; 2021 Dec; 139(12):1285-1291. PubMed ID: 34709363
[TBL] [Abstract][Full Text] [Related]
12. SCORE2 Report 17: Macular thickness fluctuations in anti-VEGF-treated patients with central or hemiretinal vein occlusion.
Scott IU; Oden NL; VanVeldhuisen PC; Ip MS; Blodi BA;
Graefes Arch Clin Exp Ophthalmol; 2022 May; 260(5):1491-1500. PubMed ID: 34842984
[TBL] [Abstract][Full Text] [Related]
13. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
Spooner K; Fraser-Bell S; Hong T; Chang A
Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
[TBL] [Abstract][Full Text] [Related]
14. SCORE2 Report 5: Vision-Related Function in Patients With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion.
Scott IU; Figueroa MJ; Oden NL; Ip MS; Blodi BA; VanVeldhuisen PC;
Am J Ophthalmol; 2017 Dec; 184():147-156. PubMed ID: 29074161
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion.
Pfau M; Fassnacht-Riederle H; Becker MD; Graf N; Michels S
Ophthalmic Res; 2015; 54(3):150-6. PubMed ID: 26413794
[TBL] [Abstract][Full Text] [Related]
16. Month 60 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion.
Scott IU; VanVeldhuisen PC; Oden NL; Ip MS; Blodi BA;
Am J Ophthalmol; 2022 Aug; 240():330-341. PubMed ID: 35461831
[TBL] [Abstract][Full Text] [Related]
17. Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema.
Wells JA; Glassman AR; Jampol LM; Aiello LP; Antoszyk AN; Baker CW; Bressler NM; Browning DJ; Connor CG; Elman MJ; Ferris FL; Friedman SM; Melia M; Pieramici DJ; Sun JK; Beck RW;
JAMA Ophthalmol; 2016 Feb; 134(2):127-34. PubMed ID: 26605836
[TBL] [Abstract][Full Text] [Related]
18. Effects of Switching to Aflibercept in Treatment Resistant Macular Edema Secondary to Retinal Vein Occlusion.
Spooner K; Fraser-Bell S; Hong T; Chang A
Asia Pac J Ophthalmol (Phila); 2020; 9(1):48-53. PubMed ID: 31990746
[TBL] [Abstract][Full Text] [Related]
19. Association of Disorganization of Retinal Inner Layers With Visual Acuity Response to Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Secondary to Retinal Vein Occlusion.
Babiuch AS; Han M; Conti FF; Wai K; Silva FQ; Singh RP
JAMA Ophthalmol; 2019 Jan; 137(1):38-46. PubMed ID: 30286219
[TBL] [Abstract][Full Text] [Related]
20. Association between early and late response in eyes with central or hemiretinal vein occlusion treated with anti-VEGF agents : SCORE2 report 12: secondary analysis of the SCORE2 clinical trial.
Khurana RN; Oden NL; VanVeldhuisen PC; Scott IU; Blodi BA; Ip MS;
Graefes Arch Clin Exp Ophthalmol; 2021 Jul; 259(7):1839-1851. PubMed ID: 33415354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
